Literature DB >> 27939465

Antiretrovirals causing severe pre-eclampsia.

Lloyd Tooke1, Linda Riemer2, Mushi Matjila3, Michael Harrison4.   

Abstract

BACKGROUND: Extremely low birth weight infants (ELBW) (⩽1000g) at our tertiary hospital have a much higher HIV exposure rate than bigger babies and are mainly delivered due to complications of pre-eclampsia. Studies investigating the effect of HIV or antiretroviral therapy on pre-eclampsia, a partially immune-mediated disease have produced contradictory results.
OBJECTIVE: To determine if there was an association between pre-eclampsia and HIV and/or antiretrovirals in the mothers of ELBW infants. STUDY
DESIGN: A prospective database was maintained for all ELBW infants born from August 2011 till January 2013. Data included maternal information such as HIV status, antiretroviral medication (duration and type) and mode and indication for delivery.
RESULTS: Of the 195 mothers who delivered ELBW infants, 46 (24%) were HIV positive. This is significantly different to the 17% HIV prevalence in mothers with bigger children (p=0.02). The main indication (59%) for delivery of the infant was hypertension related with the majority of these (94%) being classified as pre-eclampsia. Although HIV on its own showed no association (p=0.13), mothers who received greater than 4weeks of antiretrovirals were more likely to develop severe pre-eclampsia (p=0.007).
CONCLUSION: The debate about ARVs and PET is not yet over. We postulate that in a small group of susceptible women, ARVs may trigger early severe PET. It is unclear from our study if this would be due on a toxic or immune basis.
Copyright © 2016 International Society for the Study of Hypertension in Pregnancy. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27939465     DOI: 10.1016/j.preghy.2016.04.006

Source DB:  PubMed          Journal:  Pregnancy Hypertens        ISSN: 2210-7789            Impact factor:   2.899


  12 in total

1.  Combination Antiretroviral Therapy and Hypertensive Disorders of Pregnancy.

Authors:  Michele K Saums; Caroline C King; Jenna C Adams; Anandi N Sheth; Martina L Badell; Marisa Young; Lynn M Yee; Ellen G Chadwick; Denise J Jamieson; Lisa B Haddad
Journal:  Obstet Gynecol       Date:  2019-12       Impact factor: 7.661

2.  Timing of combination antiretroviral therapy (cART) initiation is not associated with stillbirth among HIV-infected pregnant women in Malawi.

Authors:  Malango T Msukwa; Olivia Keiser; Andreas Jahn; Joep J van Oosterhout; Andrew Edmonds; Nozgechi Phiri; Ronald Manjomo; Mary-Ann Davies; Janne Estill
Journal:  Trop Med Int Health       Date:  2019-04-01       Impact factor: 2.622

Review 3.  The Elusive Role of Placental Macrophages: The Hofbauer Cell.

Authors:  Michael Z Zulu; Fernando O Martinez; Siamon Gordon; Clive M Gray
Journal:  J Innate Immun       Date:  2019-04-10       Impact factor: 7.349

4.  Maternal use of drugs and preeclampsia.

Authors:  Heidi Sahlman; Marjaana Koponen; Hani El-Nezami; Kirsi Vähäkangas; Leea Keski-Nisula
Journal:  Br J Clin Pharmacol       Date:  2019-12-15       Impact factor: 4.335

5.  Combined antiretroviral therapy for HIV and the risk of hypertensive disorders of pregnancy: A systematic review.

Authors:  Ashish Premkumar; Annie M Dude; Lisa B Haddad; Lynn M Yee
Journal:  Pregnancy Hypertens       Date:  2019-05-17       Impact factor: 2.899

Review 6.  Prevention of cardiovascular disease among people living with HIV in sub-Saharan Africa.

Authors:  Samson Okello; Abdallah Amir; Gerald S Bloomfield; Katie Kentoffio; Henry M Lugobe; Zahra Reynolds; Itai M Magodoro; Crystal M North; Emmy Okello; Robert Peck; Mark J Siedner
Journal:  Prog Cardiovasc Dis       Date:  2020-02-05       Impact factor: 8.194

7.  Pregnancy outcomes among HIV-infected women who conceived on antiretroviral therapy.

Authors:  Elizabeth M Stringer; Michelle A Kendall; Shahin Lockman; Thomas B Campbell; Karin Nielsen-Saines; Fred Sawe; Susan Cu-Uvin; Xingye Wu; Judith S Currier
Journal:  PLoS One       Date:  2018-07-18       Impact factor: 3.240

Review 8.  Maternal endothelial dysfunction in HIV-associated preeclampsia comorbid with COVID-19: a review.

Authors:  Nitalia Naidoo; Jagidesa Moodley; Thajasvarie Naicker
Journal:  Hypertens Res       Date:  2021-01-20       Impact factor: 5.528

9.  A Multi-Objective Approach for Drug Repurposing in Preeclampsia.

Authors:  Eduardo Tejera; Yunierkis Pérez-Castillo; Andrea Chamorro; Alejandro Cabrera-Andrade; Maria Eugenia Sanchez
Journal:  Molecules       Date:  2021-02-03       Impact factor: 4.411

Review 10.  A Narrative Review of the Renin-Angiotensin-Aldosterone System in the Placenta and Placental Bed of HIV Infected Women of African Ancestry with Preeclampsia.

Authors:  Shoohana Singh; Jagidesa Moodley; Olive Pearl Khaliq; Thajasvarie Naicker
Journal:  Curr Hypertens Rep       Date:  2021-08-20       Impact factor: 5.369

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.